FY2025 Earnings Estimate for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Lifesci Capital issued their FY2025 EPS estimates for Inhibikase Therapeutics in a report issued on Monday, December 1st. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics’ Q4 2025 earnings at ($0.12) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.00) EPS.

Inhibikase Therapeutics Stock Up 4.9%

Shares of Inhibikase Therapeutics stock opened at $1.51 on Wednesday. The company’s fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $1.71. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $4.20. The firm has a market cap of $113.51 million, a PE ratio of -0.57 and a beta of 0.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IKT. Citadel Advisors LLC purchased a new position in shares of Inhibikase Therapeutics during the third quarter valued at approximately $116,000. ADAR1 Capital Management LLC boosted its holdings in Inhibikase Therapeutics by 2.5% in the third quarter. ADAR1 Capital Management LLC now owns 5,247,603 shares of the company’s stock valued at $8,501,000 after acquiring an additional 125,498 shares in the last quarter. BNP Paribas Financial Markets increased its position in Inhibikase Therapeutics by 70.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock valued at $25,000 after purchasing an additional 6,458 shares during the period. Vanguard Group Inc. raised its holdings in Inhibikase Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,273,339 shares of the company’s stock worth $5,303,000 after purchasing an additional 48,969 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Inhibikase Therapeutics by 74.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 49,937 shares of the company’s stock worth $81,000 after purchasing an additional 21,358 shares during the period. Institutional investors own 3.81% of the company’s stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.